Decoy Therapeutics grants director 3,000 shares
Decoy Therapeutics Inc. (DCOY) reported that director William K. McVicar received a grant of 3,000 shares of restricted common stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan.
Rhea-AI Filing Summary
Decoy Therapeutics Inc. (DCOY) reported that director William K. McVicar received a grant of 3,000 shares of restricted common stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. The award was granted at $0.00 per share and represents a compensation-related acquisition rather than an open-market purchase.
According to the grant terms, 100 percent of the restricted stock will vest on August 30, 2027. Following this award and after adjustments for prior reverse stock splits effective on August 15, 2025 and March 6, 2026, McVicar is reported to beneficially own 3,002 shares of Decoy Therapeutics common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 3,000 shares
Grant/Award
1 txn
Insider
McVicar William K.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 3,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 3,002 shares (Direct)
Footnotes (2)
- F1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
- F2. Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Key Figures
Restricted shares granted: 3,000 shares
Grant price: $0.00 per share
Vesting date: August 30, 2027
+2 more
5 metrics
Restricted shares granted
3,000 shares
Restricted common stock granted to director William K. McVicar on August 31, 2026
Grant price
$0.00 per share
Price for the 3,000-share restricted stock award
Vesting date
August 30, 2027
Date when 100% of the 3,000 restricted shares will vest
Shares beneficially owned after transaction
3,002 shares
Direct beneficial ownership reported for William K. McVicar after the grant and reverse split adjustments
Reverse stock splits referenced
2 events
Adjustments for reverse stock splits effective on August 15, 2025 and March 6, 2026
Key Terms
Restricted stock, Equity Incentive Plan, beneficially owned, reverse stock splits
4 terms
Restricted stock financial
"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Equity Incentive Plan financial
"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
beneficially owned financial
"Shares beneficially owned following the transaction have been adjusted"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
reverse stock splits financial
"adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026"
A reverse stock split is when a company combines multiple existing shares into fewer higher-priced shares—like trading four small slices of a pie for one larger slice. It doesn’t change the overall value of an investor’s holdings immediately, but it raises the per-share price and can matter to investors because it can affect market perception, stock exchange listing eligibility, and trading liquidity, and it changes share counts used in investor metrics.
FAQ
What insider transaction did Decoy Therapeutics (DCOY) report for William K. McVicar?
Decoy Therapeutics reported that director William K. McVicar received a grant of 3,000 shares of restricted common stock on August 31, 2026 as a compensation-related award under the company’s 2026 Equity Incentive Plan.
Was the DCOY insider stock grant made under a Rule 10b5-1 trading plan?
No. The filing shows the Rule 10b5-1 checkbox as not selected, and there is no footnote indicating that the reported grant to William K. McVicar was made pursuant to a Rule 10b5-1 trading plan.
Did the Decoy Therapeutics Form 4 mention any reverse stock splits affecting the insider’s holdings?
Yes. A footnote explains that McVicar’s shares beneficially owned following the transaction have been adjusted to reflect reverse stock splits effective on August 15, 2025 and March 6, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
